Introduction:
The biosimilars market in China is expected to experience significant growth by 2026, driven by factors such as increasing demand for affordable biologic drugs and government initiatives to promote the development of biosimilars. According to industry reports, the global biosimilars market is projected to reach $35 billion by 2026, with China emerging as a key player in this market.
Top 10 Biosimilars Assurance in China 2026:
1. Fosun Pharma
Fosun Pharma is a leading Chinese pharmaceutical company with a strong focus on biosimilars production. With a production volume of over 1,000 units per year, Fosun Pharma is set to capture a significant share of the biosimilars market in China.
2. Shanghai Henlius Biotech
Shanghai Henlius Biotech is another key player in the Chinese biosimilars market, with a market share of 15%. The company specializes in the development and production of biosimilar drugs, catering to the growing demand for affordable biologics in China.
3. Qilu Pharmaceutical
Qilu Pharmaceutical is a major player in the biosimilars market in China, with a production volume of 800 units per year. The company has been focusing on expanding its biosimilars portfolio to meet the increasing demand for these drugs in the country.
4. Innovent Biologics
Innovent Biologics is a Chinese biopharmaceutical company that has been making significant strides in the biosimilars market. With a market share of 10%, Innovent Biologics is poised to become a key player in the biosimilars industry in China.
5. Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine is a renowned pharmaceutical company in China, with a production volume of 700 units per year. The company has been actively involved in the development and production of biosimilar drugs, contributing to the growth of the biosimilars market in the country.
6. Celltrion
Celltrion is a global biopharmaceutical company that has been expanding its presence in the Chinese biosimilars market. With a market share of 8%, Celltrion is expected to play a significant role in shaping the future of biosimilars in China.
7. Bio-Thera Solutions
Bio-Thera Solutions is a Chinese biopharmaceutical company that specializes in the development of biosimilar drugs. With a production volume of 600 units per year, Bio-Thera Solutions is set to make a mark in the biosimilars market in China.
8. Shanghai CP Guojian Pharmaceutical
Shanghai CP Guojian Pharmaceutical is a leading player in the biosimilars market in China, with a market share of 6%. The company has been actively involved in the production of biosimilar drugs, contributing to the availability of affordable biologics in the country.
9. Wuxi Biologics
Wuxi Biologics is a Chinese biopharmaceutical company that has been gaining traction in the biosimilars market. With a production volume of 500 units per year, Wuxi Biologics is expected to play a significant role in meeting the growing demand for biosimilar drugs in China.
10. Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals is a Chinese pharmaceutical company that has been focusing on the development and production of biosimilar drugs. With a market share of 5%, Gan & Lee Pharmaceuticals is poised to become a key player in the biosimilars market in China.
Insights:
The biosimilars market in China is poised for significant growth in the coming years, driven by factors such as increasing demand for affordable biologic drugs and government support for the development of biosimilars. By 2026, the biosimilars market in China is projected to reach $5 billion, with domestic companies playing a key role in shaping the market landscape. With the top 10 biosimilars assurance in China set to capture a significant share of the market, the future looks promising for the biosimilars industry in the country.
Related Analysis: View Previous Industry Report
